MedPath

A Randomized Controlled Study on the Treatment of Helicobacter Pylori Infection with the New Combination of Traditional Chinese and Western Medicine

Phase 1
Recruiting
Conditions
Helicobacter pylori infection
Registration Number
ITMCTR2100004348
Lead Sponsor
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) Diagnosed Helicobacter pylori infection through 13C urea breath test in the past month;
(2) Aged between 18-75 years, no gender limit;
(3) The patient voluntarily signed an informed consent form.

Exclusion Criteria

(1) Have used antibiotics or bismuth within 4 weeks before treatment, or used proton pump inhibitor or H2 receptor blocker within 2 weeks;
(2) Patients with serious diseases such as cardiovascular, cerebrovascular, liver, kidney, nerve and blood system, tumors, and mental diseases;
(3) Women who are pregnant or preparing to become pregnant, and women who are breastfeeding;
(4) People with allergies or a history of allergies to the drugs in the program;
(5) Patients who are participating in or have participated in other clinical trials within 1 month.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Helicobacter pylori eradication rate;
Secondary Outcome Measures
NameTimeMethod
TCM syndrome points;
© Copyright 2025. All Rights Reserved by MedPath